Maximising clinical benefit with adequate patient management beyond the second line in mCRC-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Maximising clinical benefit with adequate patient management beyond the second line in mCRC

Published:2019 Issue:2 Volume:4 Page:e000495
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Argiles Guillem^ORCID,Arnold Dirk,Prager Gerald^ORCID,Sobrero Alberto F.,Van Cutsem Eric

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference45 articles.

1. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012;Ferlay;Eur J Cancer,2013

2. Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Van Cutsem;Ann Oncol,2014

3. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer;Van Cutsem;Ann Oncol,2016

4. A comparison of regorafenib and TAS-102 for metastatic colorectal cancer: a systematic review and network meta-analysis;Abrahao;Clin Colorectal Cancer,2018

5. Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2'-deoxyribonucleosides;Fukushima;Biochem Pharmacol,2000

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. REVISÃO INTEGRATIVA DOS BENEFÍCIOS DO TAS-102 NO TRATAMENTO DE TERCEIRA LINHA DO CÂNCER COLORRETAL METASTÁTICO;Revista Contemporânea;2024-07-04

2. Concept and feasibility of the Augsburg Longitudinal Plasma Study (ALPS) – a prospective trial for comprehensive liquid biopsy-based longitudinal monitoring of solid cancer patients;Journal of Laboratory Medicine;2024-04-19

3. The REWRITE Study – REal-WoRld effectIveness of TrifluridinE/tipiracil in Patients with Previously Treated Metastatic Colorectal Cancer;Clinical Oncology;2023-10

4. China special issue on gastrointestinal tumors‐Cetuximab retreatment plus camrelizumab and liposomal irinotecan in patients with RAS wild‐type metastatic colorectal cancer: Cohort B of the phase II CRACK study;International Journal of Cancer;2023-05-10

5. Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial;British Journal of Cancer;2023-03-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3